Response to Repotrectinib After Development of NTRK Resistance Mutations on First- and Second-Generation TRK Inhibitors

JCO Precis Oncol. 2023 May:7:e2200697. doi: 10.1200/PO.22.00697.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Mutation
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles* / pharmacology
  • Pyrazoles* / therapeutic use
  • Receptor, trkA* / genetics

Substances

  • repotrectinib
  • Pyrazoles
  • Receptor, trkA
  • Protein Kinase Inhibitors